Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Borderline personality disorders
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical Development & Commercialization

    • Most Recent Events

    • 27 Jan 2022 Status changed from active, no longer recruiting to completed.
    • 18 Aug 2021 According to an Otsuka Pharmaceutical media release, The company in collaboration with Ludbeck plan to submit the detailed trial outcomes for scientific publication at a future date.
    • 18 Aug 2021 Primary endpoint has not been met. (Change from baseline in the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) total score), according to an Otsuka Pharmaceutical media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top